J. Tankovic et al., IN-VIVO SELECTION DURING PEFLOXACIN THERAPY OF A MUTANT OF STAPHYLOCOCCUS-AUREUS WITH 2 MECHANISMS OF FLUOROQUINOLONE RESISTANCE, Antimicrobial agents and chemotherapy, 38(5), 1994, pp. 1149-1151
Staplylococcus aureus BM4626 (ciprofloxacin MIC, 0.5 mu g/ml) and BM46
27 (ciprofloxacin MIC, 32 mu g/ml) were isolated from the same patient
before and during pefloxcin therapy for septic tibial nonunion, respe
ctively. The two strains had similar serotypes and indistinguishable p
hage types and SmaI-generated restriction fragment length polymorphism
s. Portions of the gyrA (codons 60 to 120) and the gyrB (codons 420 to
480) genes of each clinical isolate were amplified by PCR and sequenc
ed. Strain BM4627 had a serine-to-leucine substitution resulting from
a cytosine-to-thymidine mutation at codon 84 of gvrA relative to the s
equence of the gvrA gene of BM4626. Norfloxacin accumulation, measured
in a whole-cell uptake assay, was significantly lower in BM4627 than
BM4626. These data indicate that double mutants can be selected in viv
o under fluoroquinolone therapy.